Search

Your search keyword '"Chemnitz, Jens-Marcus"' showing total 17 results
Start Over Author "Chemnitz, Jens-Marcus"
17 results on '"Chemnitz, Jens-Marcus"'

2. Preinfection laboratory parameters may predict COVID‐19 severity in tumor patients

Author

Kiani, Alexander, primary, Roesch, Romina, additional, Wendtner, Clemens M., additional, Kullmann, Frank, additional, Kubin, Thomas, additional, Südhoff, Thomas, additional, Augustin, Marinela, additional, Schaich, Markus, additional, Müller‐Naendrup, Clemens, additional, Illerhaus, Gerald, additional, Hartmann, Frank, additional, Hebart, Holger, additional, Seggewiss‐Bernhardt, Ruth, additional, Bentz, Martin, additional, Späth‐Schwalbe, Ernst, additional, Reimer, Peter, additional, Kaiser, Ulrich, additional, Kapp, Markus, additional, Graeven, Ullrich, additional, Chemnitz, Jens‐Marcus, additional, Baesecke, Jörg, additional, Lambertz, Helmut, additional, and Naumann, Ralph, additional

Published
2021
Full Text
View/download PDF

3. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

Author

Stasik, Sebastian, Eckardt, Jan-Niklas, Kramer, Michael, Röllig, Christoph, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan, Herbst, Regina, Hänel, Mathias, Frickhofen, Norbert, Noppeney, Richard, Kaiser, Ulrich, Baldus, Claudia D., Kaufmann, Martin, Rácil, Zdenek, Platzbecker, Uwe, Berdel, Wolfgang E., Mayer, Jiri, Serve, Hubert, Müller-Tidow, Carsten, Ehninger, Gerhard, Bornhäuser, Martin, Schetelig, Johannes, Middeke, Jan M., Thiede, Christian, Schulz-Abelius, Armin, Trepel, Martin, Teichmann, Martina, Kiani, Alexander, Glaß, Bertram, Görner, Martin, Behringer, Dirk, Kullmer, Johannes, Lamberti, Christof, Schmidt-Hieber, Martin, Flaßhove, Michael, MacKensen, Andreas, Hanoun, Maher, Kiehl, Michael, Höffkes, H.-G., Müller, Lutz Peter, Dürk, Heinz Albert, Held, Gerhard, Repp, Roland Peter, Baldus, Claudia, Chemnitz, Jens-Marcus, Klein, Stefan, Wilhelm, Martin, Schubert, Jörg, Meinhardt, Achim, Geer, Thomas, Ritter, Markus, Aulitzky, Walter Erich, and Heinz, Natalia

Subjects
Neuroblastoma RAS viral oncogene homolog, Oncology, musculoskeletal diseases, medicine.medical_specialty, NPM1, congenital, hereditary, and neonatal diseases and abnormalities, Medizin, Protein Tyrosine Phosphatase, Non-Receptor Type 11, Context (language use), 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Phosphoprotein Phosphatases, medicine, Humans, skin and connective tissue diseases, 030304 developmental biology, 0303 health sciences, Myeloid Neoplasia, business.industry, Remission Induction, Hazard ratio, Cytogenetics, Myeloid leukemia, Hematology, Odds ratio, Prognosis, 3. Good health, PTPN11, Leukemia, Myeloid, Acute, 030220 oncology & carcinogenesis, Mutation, business, Nucleophosmin
Abstract

The tyrosine-protein phosphatase nonreceptor type 11 (PTPN11) is an important regulator of RAS signaling and frequently affected by mutations in patients with acute myeloid leukemia (AML). Despite the relevance for leukemogenesis and as a potential therapeutic target, the prognostic role is controversial. To investigate the prognostic impact of PTPN11 mutations, we analyzed 1529 adult AML patients using next-generation sequencing. PTPN11 mutations were detected in 106 of 1529 (6.93%) patients (median VAF: 24%) in dominant (36%) and subclonal (64%) configuration. Patients with PTPN11 mutations were associated with concomitant mutations in NPM1 (63%), DNMT3A (37%), and NRAS (21%) and had a higher rate of European LeukemiaNet (ELN) favorable cytogenetics (57.8% vs 39.1%; P < .001) and higher white blood cell counts (P = .007) compared with PTPN11 wild-type patients. In a multivariable analysis, PTPN11 mutations were independently associated with poor overall survival (hazard ratio [HR]: 1.75; P < .001), relapse-free survival (HR: 1.52; P = .013), and a lower rate of complete remission (odds ratio: 0.46; P = .008). Importantly, the deleterious effect of PTPN11 mutations was confined predominantly to the ELN favorable-risk group and patients with subclonal PTPN11 mutations (HR: 2.28; P < .001) but not found with dominant PTPN11 mutations (HR: 1.07; P = .775), presumably because of significant differences within the rate and spectrum of associated comutations. In conclusion, our data suggest an overall poor prognostic impact of PTPN11 mutations in AML, which is significantly modified by the underlying cytogenetics and the clonal context in which they occur.

Published
2021

6. Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study

Author

Gruenwald, Viktor, Karch, Annika, Schuler, Markus, Schoeffski, Patrick, Kopp, Hans-Georg, Bauer, Sebastian, Kasper, Bernd, Lindner, Lars H., Chemnitz, Jens-Marcus, Crysandt, Martina, Stein, Alexander, Steffen, Bjoern, Richter, Stephan, Egerer, Gerlinde, Ivanyi, Philipp, Zimmermann, Silke, Liu, Xiaofei, Kunitz, Annegret, Gruenwald, Viktor, Karch, Annika, Schuler, Markus, Schoeffski, Patrick, Kopp, Hans-Georg, Bauer, Sebastian, Kasper, Bernd, Lindner, Lars H., Chemnitz, Jens-Marcus, Crysandt, Martina, Stein, Alexander, Steffen, Bjoern, Richter, Stephan, Egerer, Gerlinde, Ivanyi, Philipp, Zimmermann, Silke, Liu, Xiaofei, and Kunitz, Annegret

Abstract

PURPOSEDoxorubicin is a standard of care in patients with advanced, inoperable soft tissue sarcoma (STS). We tested whether pazopanib has efficacy comparable to that of doxorubicin in elderly patients with STS and offers superior tolerability for hematologic toxicity.PATIENTS AND METHODSPatients age 60 years or older without previous systemic treatment for progressive advanced or metastatic STS who had Eastern Cooperative Oncology Group performance status of 0 to 2 and adequate organ function were included. Treatment consisted of pazopanib 800 mg once per day or doxorubicin 75 mg/m(2) once every 3 weeks (<= 6 cycles) after being randomly assigned in a 2:1 ratio. Noninferiority was assumed for progression-free survival (PFS), if the upper limit of the 95% CI for the hazard ratio (HR) was less than 1.8. Neutropenia and febrile neutropenia were key secondary end points. The European Organisation for Research and Treatment of Cancer (30-item) Quality of Life Questionnaire and geriatric assessment were used to measure patient-reported outcomes. Cox regression analysis and Kaplan-Meier curves were used for analysis.RESULTSPazopanib and doxorubicin were given to 81 and 39 patients, respectively. The median age was 71 years (range, 60-88 years). PFS was noninferior (HR, 1.00; 95% CI, 0.65 to 1.53) and the incidence of grade 4 neutropenia and febrile neutropenia favored pazopanib. Objective response rates for pazopanib and doxorubicin were 12.3% and 15.4%, respectively. Overall survival did not differ significantly between arms (HR, 1.08; 95% CI, 0.68 to 1.72; P = .735). Geriatric assessment revealed 2 or more comorbidities in 15.8% of the patients and impairment of activities of daily living in 28.3% of patients.CONCLUSIONPazopanib was noninferior to doxorubicin, rendering pazopanib a putative therapeutic option in the first-line treatment of STS in patients age 60 years or older. The distinct adverse event profile may be used to counsel patients and tailor therapy to indiv

Published
2020

7. Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study

Author

Grünwald, Viktor, primary, Karch, Annika, additional, Schuler, Markus, additional, Schöffski, Patrick, additional, Kopp, Hans-Georg, additional, Bauer, Sebastian, additional, Kasper, Bernd, additional, Lindner, Lars H., additional, Chemnitz, Jens-Marcus, additional, Crysandt, Martina, additional, Stein, Alexander, additional, Steffen, Björn, additional, Richter, Stephan, additional, Egerer, Gerlinde, additional, Ivanyi, Philipp, additional, Zimmermann, Silke, additional, Liu, Xiaofei, additional, and Kunitz, Annegret, additional

Published
2020
Full Text
View/download PDF

8. Quality of life and added value of a tailored palliative care intervention in patients with soft tissue sarcoma undergoing treatment with trabectedin: a multicentre, cluster-randomised trial within the German Interdisciplinary Sarcoma Group (GISG)

Author

Hentschel, Leopold, primary, Richter, Stephan, additional, Kopp, Hans-Georg, additional, Kasper, Bernd, additional, Kunitz, Annegret, additional, Grünwald, Viktor, additional, Kessler, Torsten, additional, Chemnitz, Jens Marcus, additional, Pelzer, Uwe, additional, Schuler, Ulrich, additional, Freitag, Janet, additional, Schilling, Andrea, additional, Hornemann, Beate, additional, Arndt, Karin, additional, Bornhäuser, Martin, additional, and Schuler, Markus Kajo, additional

Published
2020
Full Text
View/download PDF

11. Randomized comparison of pazopanib (PAZ) and doxorubicin (DOX) in the first line treatment of metastatic soft tissue sarcoma (STS) in elderly patients (pts): Results of a phase II study (EPAZ).

Author

Grunwald, Viktor, Kunitz, Annegret, Schuler, Markus Kajo, Schoffski, Patrick, Kopp, Hans-Georg, Bauer, Sebastian, Kasper, Bernd, Lindner, Lars H., Chemnitz, Jens-Marcus, Crysandt, Martina Margrit, Stein, Alexander, Steffen, Bjoern, Egerer, Gerlinde, Zimmermann, Silke, Karch, Annika, Grunwald, Viktor, Kunitz, Annegret, Schuler, Markus Kajo, Schoffski, Patrick, Kopp, Hans-Georg, Bauer, Sebastian, Kasper, Bernd, Lindner, Lars H., Chemnitz, Jens-Marcus, Crysandt, Martina Margrit, Stein, Alexander, Steffen, Bjoern, Egerer, Gerlinde, Zimmermann, Silke, and Karch, Annika

Published
2018

12. Randomized comparison of pazopanib (PAZ) and doxorubicin (DOX) in the first line treatment of metastatic soft tissue sarcoma (STS) in elderly patients (pts): Results of a phase II study (EPAZ).

Author

Grünwald, Viktor, primary, Kunitz, Annegret, additional, Schuler, Markus Kajo, additional, Schoffski, Patrick, additional, Kopp, Hans-Georg, additional, Bauer, Sebastian, additional, Kasper, Bernd, additional, Lindner, Lars H, additional, Chemnitz, Jens-Marcus, additional, Crysandt, Martina Margrit, additional, Stein, Alexander, additional, Steffen, Bjoern, additional, Egerer, Gerlinde, additional, Zimmermann, Silke, additional, and Karch, Annika, additional

Published
2018
Full Text
View/download PDF

13. EPAZ: A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma of the Working Group Medical Oncology (AIO) and German Interdisciplinary Sarcoma Group (GISG).

Author

Gruenwald, Viktor, primary, Kunitz, Annegret, additional, Schuler, Markus Kajo, additional, Kopp, Hans-Georg, additional, Kasper, Bernd, additional, Lindner, Lars, additional, Chemnitz, Jens-Marcus, additional, Stein, Alexander, additional, Schöffski, Patrick, additional, Steffen, Bjoern, additional, Bauer, Sebastian, additional, Egerer, Gerlinde, additional, Kneba, Michael, additional, Crysandt, Martina, additional, and Koch, Armin, additional

Published
2015
Full Text
View/download PDF

14. Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial

Author

von Tresckow, Bastian, Boell, Boris, Eichenauer, Dennis, Beschorner, Denissa, Knop, Stefan, Goebeler, Maria-Elisabeth, Chemnitz, Jens Marcus, Hallek, Michael, Engert, Andreas, Huebel, Kai, von Tresckow, Bastian, Boell, Boris, Eichenauer, Dennis, Beschorner, Denissa, Knop, Stefan, Goebeler, Maria-Elisabeth, Chemnitz, Jens Marcus, Hallek, Michael, Engert, Andreas, and Huebel, Kai

Published
2014

15. Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial

Author

von Tresckow, Bastian, primary, Boell, Boris, additional, Eichenauer, Dennis, additional, Beschorner, Denissa, additional, Knop, Stefan, additional, Goebeler, Maria-Elisabeth, additional, Chemnitz, Jens Marcus, additional, Hallek, Michael, additional, Engert, Andreas, additional, and Huebel, Kai, additional

Published
2013
Full Text
View/download PDF

16. Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia

Author

Chemnitz, Jens Marcus, primary, von Lilienfeld-Toal, Marie, additional, Holtick, Udo, additional, Theurich, Sebastian, additional, Shimabukuro-Vornhagen, Alexander, additional, Krause, Anke, additional, Brossart, Peter, additional, Hallek, Michael, additional, and Scheid, Christof, additional

Published
2011
Full Text
View/download PDF

17. Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial.

Author

von Tresckow B, Boell B, Eichenauer D, Beschorner D, Knop S, Goebeler ME, Chemnitz JM, Hallek M, Engert A, and Huebel K

Subjects
Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized adverse effects, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Cetuximab, Humans, Multiple Myeloma mortality, Neoplasm Recurrence, Local, Treatment Outcome, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents therapeutic use, ErbB Receptors antagonists & inhibitors, Multiple Myeloma drug therapy, Multiple Myeloma pathology
Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results